Tirzepatide 10 mg

ACTIVE HALF-LIFE 5 days
CLASSIFICATION Dual GIP and GLP-1 Receptor Agonist
MANUFACTURER Beligas - US
WAREHOUSE USA Warehouse 2
SUBSTANCE GIP/GLP-1 RA

Introducing Tirzepatide, a cutting-edge synthetic peptide celebrated for its remarkable ability to regulate glucose levels effectively. By enhancing both first- and second-phase insulin secretion while simultaneously reducing glucagon levels, this innovative peptide operates in a glucose-dependent manner, making it a vital tool for managing type 2 diabetes.

Extensive research demonstrates that Tirzepatide not only slows gastric emptying but also lowers both fasting and post-meal glucose levels, curbs appetite, and supports weight loss efforts in those living with type 2 diabetes. Additionally, it has shown potential to improve insulin sensitivity, further aiding in glucose management.

This peptide is uniquely structured with a C20 fatty diacid linked through a hydrophilic linker at the lysine residue in position 20, granting it a robust binding affinity to plasma albumin, which significantly extends its half-life.

Glucagon-like peptide-1 (GLP-1) receptors (GLP-1R) are widely present in the body, particularly in pancreatic beta-cells and the gastrointestinal system, where they play a pivotal role in regulating glucose. GLP-1R signaling enhances glucose-stimulated insulin secretion, slows gastric transit, reduces plasma glucagon levels, and promotes weight loss by curbing appetite through brain pathways. Complementing this, glucose-dependent insulinotropic polypeptide (GIP) works hand in hand with GLP-1 to maintain glucose equilibrium by stimulating insulin secretion from pancreatic beta-cells, with GIP being primarily responsible for the insulinotropic response to food intake.

While the exact mechanism of Tirzepatide remains partially understood, its dual action on GIP and GLP-1R is believed to be crucial for its effects on glycemic control and weight management. Studies reveal that administering GIP alongside a GLP-1R agonist results in a more pronounced insulin response and greater suppression of glucagon secretion compared to administering either hormone alone. Tirzepatide showcases a strong binding affinity for both GIP and GLP-1R, with receptor binding affinity for GIP comparable to that of native GIP, albeit five times less effective at binding GLP-1R than its native counterpart. It effectively activates the GLP-1R signaling pathway, promoting glucose-dependent insulin secretion via either GIP receptor (GIPR) or GLP-1R. However, further investigation is essential to fully elucidate the role of GIPR activation in Tirzepatide's mechanism, as current evidence from preclinical and clinical studies concerning its impact on glycemic control and weight management remains varied.